A Covid-19 threat to business acquisitions
20 key healthcare transactions, most struck before the Covid-19 pandemic hit, have yet to be formally completed.
A handful of huge gains stand out among mid and small-cap biotechs
Drug makers from across the globe feature in 2019’s list of best performing small biotech stocks, from Galapagos to Daiichi Sankyo to Arrowhead.
Few biopharma buyouts in quiet third quarter
The $6.6bn of M&A deals announced by drug makers in third quarter of 2018 marks the slowest three-month period since 2013.